UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 338

Sortiert nach

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Annals of oncology, 2021-01, Vol.32 (1), p.77-84

2021

Volltextzugriff (PDF)

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer

European journal of cancer (1990), 2019-09, Vol.119, p.158-167

2019

Volltextzugriff (PDF)

Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy

Annals of oncology, 2021-11, Vol.32 (11), p.1434-1441

2021

Volltextzugriff (PDF)

Trifluridine/tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study

Annals of oncology, 2018-06, Vol.29, p.v65-v65

2018

Volltextzugriff (PDF)

Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study)

Annals of oncology, 2018-06, Vol.29, p.v69-v69

2018

Volltextzugriff (PDF)

Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)

Annals of oncology, 2016-06, Vol.27 (6), p.1143-1148

2016

Volltextzugriff (PDF)

Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study

Annals of oncology, 2018-10, Vol.29, p.viii199-viii199

2018

Volltextzugriff (PDF)

A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)

Annals of oncology, 2018-11, Vol.29, p.ix138-ix138

2018

Volltextzugriff (PDF)

SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results

Annals of oncology, 2018-06, Vol.29, p.v95-v95

2018

Volltextzugriff (PDF)

Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results

Annals of oncology, 2018-11, Vol.29, p.ix34-ix35

2018

Volltextzugriff (PDF)

Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration

Annals of oncology, 2018-06, Vol.29, p.v110-v110

2018

Volltextzugriff (PDF)

A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

Annals of oncology, 2018-06, Vol.29, p.v71-v71

2018

Volltextzugriff (PDF)

Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii166

2018

Volltextzugriff (PDF)

Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress

Annals of oncology, 2018-06, Vol.29, p.v83-v83

2018

Volltextzugriff (PDF)

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial

Annals of oncology, 2018-11, Vol.29, p.ix28-ix29

2018

Volltextzugriff (PDF)

Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration

Annals of oncology, 2017-09, Vol.28, p.v614-v614

2017

Volltextzugriff (PDF)

P-159Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii47-ii47

2016

Volltextzugriff (PDF)

Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii156

2018

Volltextzugriff (PDF)

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

ESMO open, 2023-10, Vol.8 (5), p.101636-101636, Article 101636

2023

Volltextzugriff (PDF)

pH-sensing nano-crystals of carbonate apatite: Effects on intracellular delivery and release of DNA for efficient expression into mammalian cells

Gene, 2006-07, Vol.376 (1), p.87-94

2006

Volltextzugriff (PDF)

95P Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer

Annals of oncology, 2020-11, Vol.31, p.S1279-S1279

2020

Volltextzugriff (PDF)

Novel in vitro model of urea cycle disorder using citrullinemia type I patient-derived iPSC s

HPB (Oxford, England), 2016-04, Vol.18, p.e300-e300

2016

Volltextzugriff (PDF)

P-82 Clinical features of Japanese patients with detailed RAS/BRAF mutant colorectal cancer

Annals of oncology, 2020-07, Vol.31, p.S116

2020

Volltextzugriff (PDF)

Structure of Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein: Superhelical Homo-Oligomers and the Role of Caspase-3 Cleavage

Journal of Virology, 2012-11, Vol.86 (22), p.12294-12303

2012

Volltextzugriff (PDF)

P-78 A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis

Annals of oncology, 2022-06, Vol.33, p.S275

2022

Volltextzugriff (PDF)

1 – 25 von 338

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(284)
Mit Volltextzugriff
(301)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(162)
Physical Sciences
(99)
Exact Sciences And Technology
(67)
Technology
(51)
Applied Sciences
(49)
Humans
(48)
Life Sciences & Biomedicine
(46)
Physics
(40)
Polymer Science
(39)
Engineering
(32)
Physicochemistry Of Polymers
(31)
Organic Polymers
(30)
Properties And Characterization
(29)
Physics, Applied
(28)
Female
(27)
Male
(26)
Engineering, Electrical & Electronic
(25)
Organic Chemistry
(25)
Chemistry
(24)
Middle Aged
(23)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer

Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy

Trifluridine/tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study

Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study)

Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)

Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study

A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)

SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results

Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results

Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration

A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer

Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial

Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration

P-159Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study

Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

pH-sensing nano-crystals of carbonate apatite: Effects on intracellular delivery and release of DNA for efficient expression into mammalian cells

95P Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer

Novel in vitro model of urea cycle disorder using citrullinemia type I patient-derived iPSC s

P-82 Clinical features of Japanese patients with detailed RAS/BRAF mutant colorectal cancer

Structure of Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein: Superhelical Homo-Oligomers and the Role of Caspase-3 Cleavage

P-78 A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis

Suchergebnisse filtern